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Abstract
Background: Episodes of explosive rage and violence
comprise a symptom complex which can have a
devastating effect on a person’s life. In the
community this behavior is seen as workplace
violence, domestic abuse and road rage, while in the
clinical setting, this behavior is rarely mentioned by
patients, despite evidence that it can signify an
important biological disorder that may afflict more
than three percent of the population.
Discussion: Patients are often reluctant to seek help
for episodic attacks of rage, especially attacks which
are accompanied by physical violence. Although, in
the past, clinicians have had few treatment options to
offer, recent neuroscience advances have created new
possibilities to understand and help patients with this
neglected problem. No formal medical guidelines for
treating violence exist; however, many patients can be
helped by diagnosis, referral and treatment. Treatment
can include pharmaceuticals and nutrients, as well as
referral for anger management or behavioral therapy.
Summary: The astute clinician has an opportunity to
positively impact an important problem through the
diagnosis and treatment of patients with symptoms
of intermittent explosive disorder.
Keywords: aggression, alcoholism, psychopharmacol-
ogy, violence, domestic abuse, prevention, neurobiol-
ogy, treatment, domestic violence
Background
The symptom complex characterized by repeated epi-
sodes of explosive rage and violence, disproportionate to
any provocation, is rarely a patient’s chief complaint, but
it is a common problem none the less. For the afflicted
individual, such a complaint may have profound effects
on their self-esteem, their interpersonal relationships,
and even on their ability to function in society. While
some violence can be premeditated, goal directed or
related to antisocial, callous unemotional traits, it is
rather the category of violence described as affective
aggression, (that is, reactive, defensive or hostile aggres-
sion) associated with fear and threat which will be the
focus of this paper [1]. For most clinicians, the clinical
perspective of violence as seen with Intermittent Explo-
sive Disorder, specified by DSM-IV to encompass “sev-
eral discrete episodes of failure to resist aggressive
impulses that result in serious assaultive acts or destruc-
tion of property”, with the further specification that “the
degree of aggressiveness expressed during the episodes is
grossly out of proportion to any precipitating psychologi-
cal stressors” [2], provides a framework for addressing
this issue from a clinical standpoint. When afflicted indi-
viduals express a concern about this unwanted behavior,
it becomes an issue which clearly warrants the concern
of their physician. This paper will give a brief review of
the clinical approach to this, often ignored, yet common
problem.
Intermittent explosive disorder has a prevalence of 3.9%,
suggesting that each year in the United States, it is respon-
sible for more than 30 million violent assaults [3]. When
manifested as domestic abuse, road rage or workplace vio-
lence, such behavior is commonly attributed to cultural
factors, social stress, economic deprivation or substance
abuse. Much more needs to be known about these beha-
viors; however, recent advances in neuroscience allow for
a more complete understanding, which accounts for biolo-
gical factors amenable to medical treatment [4-8].
A number of factors have limited the benefits which a
neurobiological perspective on violence might bring.
* Correspondence: umhau@jhu.edu
1Laboratory of Clinical and Translational Studies, National Institutes of Health,
National Institute on Alcohol Abuse and Alcoholism, 10 Center Drive,
Building 10-CRC Hatfield Center, Room 1-5330, Bethesda, MD, 20892-1108,
USA
Full list of author information is available at the end of the article
Umhau et al. BMC Medicine 2012, 10:146
http://www.biomedcentral.com/1741-7015/10/146
© 2012 Umhau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Perpetrators may be unaware that they could benefit
from medical intervention. Clinicians may be uncomfor-
table dealing with an area of diagnosis and treatment
with which they are unfamiliar. Considering a violent
perpetrator to be responsible for their actions may be a
critical legal policy to uphold, but such a policy may
impede diagnosis. All these factors ultimately work
together to deny the benefits of modern clinical care to
individuals who may urgently need it.
This article will provide a brief overview of the diag-
nosis and treatment of chronic violent behavior. A brief
discussion of the neurobiology of violence will be pre-
sented and legal aspects of treatment will also be dis-
cussed in an effort to encourage clinical interest in what
may be one of the most neglected areas of medicine.
Discussion
Neurobiology
One way to understand the biological basis for explosive
types of rage and violence is to consider it as behavior
which promotes survival in the face of threat [6]. Although
many “threats” are psychological, rather than physical, the
autonomic nervous system is aroused in either case. The
resulting rage response is an innate behavior that rises
from the limbic system (for example, amygdale and related
structures) and is associated with palpitations, sweating,
tachypnea and trembling [9,10]. The individual’s own per-
ception of these symptoms may incite further arousal in a
positive feedback loop on the limbic system response. The
prefrontal cortex and the anterior cingulate gyus provide a
“top-down” inhibition of this limbic response while evalu-
ating whether a physical or psychological “threat” is a
harmless insult or a serious challenge to survival [9]. Con-
trolling this limbic response appropriately is one of the
most time critical functions of the frontal cortex; the sero-
toninergic neurotransmitter system is thought to be criti-
cal in this process [11]. The rapid appraisal of potential
threats is especially sensitive to perturbation, such as the
sensory processing distortions caused by metabolic distur-
bances or substance abuse [9]. It is the prefrontal cortex
which allows for the consideration of nuanced and non-
violent responses to any specific “threat” [12]. However,
when violence is called for, limbic (for example, amygdale)
activation will shut down the calming input from the pre-
frontal cortex in order to promote quick reactions and
efficient fighting [13].
Various neurological disorders can disrupt the critical
and sensitive processing necessary for appropriate beha-
vior in response to perceived threat [9]. Neuroimaging
studies suggest that in the pathological situation, calming
cortical inputs are shut down when they should not be,
permitting exaggerated and inappropriate limbic arousal
and rage [8,12]. Impaired control of the limbic system
rage response in this situation explains how a domestic
violence perpetrator could physically attack their spouse
with no apparent concern for the consequences. If corti-
cal control is dysfunctional, relatively minor slights to the
ego might be misinterpreted as overwhelming threat,
leading to a violent response [12]. Acute psychological
stress as well as social and cultural factors may interact
with neurobiological deficits to create a situation where
inappropriate violence becomes frequent [14].
Diagnosis
Episodes of explosive rage and violence can be a defin-
ing feature of a patient’s personal life; however, in the
same way that patients can be reluctant to admit they
have depression; they are even more ashamed to admit
they have violent behavior. Often patients experience
remorse, but not always. Simply asking during a history
and physical examination, “Do you lose your temper?
Do you do things when you are angry that you later
regret?” can lead an individual to discuss behaviors that
they would otherwise never initiate. If a clinician can
suspend judgment about their patient’s behavior and
discuss situations without making disparaging remarks,
patients can potentially overcome their denial and face
the destructive effects of their “anger problem”. The use
of valid scales, such as the STAXI [15] and the BPAQ-
SF [16] may also be helpful in identifying such patients.
Between episodes, there is no classical way for someone
with rage and violence to present for care; however,
considering the association between violence and alco-
hol, individuals undergoing alcoholism detoxification
may be more likely to benefit from screening. Impulsive
aggression is frequently found in a co-morbid associa-
tion with substance abuse and with personality disor-
ders. Also, patients presenting with injuries suffered as a
result of interpersonal violence are themselves at risk
for having inappropriate attacks of rage [17]. When
patients do present with violence, it is a common cause
for involuntary commitment to a psychiatric facility and
acute therapy [18,19].
Although in many cases violence may be a behavior
simply learned from the patient’s social and cultural
background, the unique role of the clinician is to criti-
cally evaluate each patient for biological factors which
can be treated, or refer the patient to a physician who
can [20-24]. Many disorders which affect the central ner-
vous system have been associated with violence
[20,25-29]. Episodic attacks of rage and violence are not a
classic presentation of any specific disorder, but this
behavior can arise from diverse causes, including epi-
lepsy, nutritional deficiencies, brain tumors, toxic expo-
sures and encephalopathy from endocrine, metabolic or
infectious disorders [18]. Closed head injuries can leave
patients with no objective sign of their injury but with a
dramatic predilection for episodes of impulsive rage [27].
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Both acute and chronic substance abuse, for example,
alcohol, and stimulants, can contribute to violence [30].
Depression, mania, post-traumatic stress disorder and
schizophrenia may be associated with irritably, rage and
violence [20]. (See Table 1)
It is important to note that not all instances of violence
have serious underlying pathology. For example, the
aggression associated with hypoglycemia can be simply
treated with food. Identifying the precise biological fac-
tors contributing to violence can be difficult as multiple
predisposing conditions often coexist in one patient. As
with any neurological issue, diagnostic testing is led by
the symptom presentation and physical exam. For exam-
ple, if temporal lobe seizures are suspected, an electroen-
cephalogram (EEG) may be indicated [26]. In most cases,
however, the physical exam will be normal, and a precise
diagnosis will be elusive. In such a situation, empiric
treatment may be indicated.
Treatment
Although no drugs have a Food and Drug Administration
(FDA) approved indication for violence, many therapeu-
tic options have been tested in randomized, placebo-
controlled double-blind trials [20,28,31]. (see Table 2)
Psychiatrists use various classes of drugs as treatment for
violence, but treatment guidelines have not been estab-
lished. The point of this article is to introduce existent
therapeutic options rather than to provide a detailed
review of pharmacotherapy, which has been reviewed
elsewhere [18,20,25,31-40]. Medication is not a panacea;
all types of violence are not amenable to pharmacological
therapy. For example, treatment with the classic anticon-
vulsant phenytoin was shown to reduce impulsive
but not premeditated violence [41]. In previous reviews
the use of anticonvulsants, beta blockers and atypical
antipsychotic agents has been described in detail
[20,31,40-49]. For more than 40 years, lithium has been
used in many populations to treat violence [50].
Serotonin reuptake inhibitors are commonly used in the
setting of depression but can also be effective for redu-
cing chronic anger [20]. Serotonin reuptake inhibitors
are often initially used at low doses to guard against any
paradoxical exacerbating effect [31,22,41]. Since the use
of all of these medications for reducing violence is “off
label”, it is important to carefully monitor for any adverse
effects which can in some instances cause an increase in
irritability and aggression [22,40].
Nutritional factors, especially the essential omega-3
fatty acids, docosahexaenoic acid (DHA) and eicosapen-
taenoic acid (EPA) are critical components of the nervous
system, but can be deficient in the diet [51-53]. Some
controlled trials suggest that these nutrients may reduce
aggression and produce other benefits with few side
effects [54-56]. In recognition of this, the American Psy-
chiatric Association recommends that individuals with
mood, impulse-control or psychotic disorders consume 1
gram of EPA + DHA per day [57]. When essential fatty
acids were administered with multiple vitamins to young
men in prison, violence was reduced by one third [58], a
finding which was later replicated [59]. Although there
are many more studies demonstrating the effectiveness of
prescription pharmaceuticals than there are of studies
testing nutrients, omega-3 fatty acid (that is, fish oil) and
vitamins have the benefit that they may be readily
accepted by patients who desire a more “natural” type of
therapy without the stigma and serious side effects which
sometimes accompany psychotropic medications [60].
Because of the potential for nutritional therapy to address
the problem of violence on a public health basis, there is
a critical need for more research to resolve controversies
in this area.
Substance abuse treatment as therapy for
aggressive behavior
Alcoholism may be the most common condition asso-
ciated with violence; alcohol is thought to have a
Table 1 Some medical conditions associated with episodic rage and violence
Psychiatric Organic brain syndrome [35], Korsakoff’s psychosis [86], bipolar disorder [87], psychoactive substance intoxication and
withdrawal [88], psychotic disorders [89], premenstrual dysphoric disorder [90], post-traumatic stress disorder [22], panic
disorder [4], generalized anxiety disorder [91], antisocial personality disorder [92], borderline personality disorder [92],
personality disorders [92], attention deficit disorder [93], major depressive disorder [94].
Neurological Brain tumors/lesions [95], head injury [27], Parkinson’s disorder [96], seizure disorder [26], multiple sclerosis [97], normal pressure
hydrocephalus [98], autism [34], Wilson’s disease [29], Huntington’s disease [99], dementia [100], stroke [101].
Nutritional
deficiency
Omega-3 fatty acids [56], folate [29], cobalamin (B12) [102,103], thiamine [104,105], iron [106], lithium [107], magnesium [53,108],
tryptophan [109], pyridoxine [29].
Medical and toxic Alcohol [21,110], cocaine [21,111], manganese [29,112], organophosphorous compounds [29,113], phencyclidine (PCP) [114],
lysergic acid diethylamide (LSD) [101,115], heroin [101,116], amphetamines [117], benzodiazepines [117,118], prescription drugs
[117,119], anabolic steroids [117].
Metabolic/
Endocrine
Hypoglycaemia [101,117,120], hepatic encephalopathy [121], fluid and electrolyte imbalances [119], disorders of the thyroid,
parathyroid and adrenal glands [29,122], hypoxia [101].
Miscellaneous Intermittent Porphoria [123], chronic pain [124], sleep disorders [29,125], anemia [126], vasculitis [119], meningitis/encephalitis
[101], syphilis [102].
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disinhibiting effect on aggressive behavior [6]. Reports
suggest that most severe interpersonal violence occurs
when the perpetrator is intoxicated. Cocaine abuse is
also associated with violence [30]. Not surprisingly,
recent research has found that substance abuse treat-
ment can reduce the prevalence of violent behavior by
more than half [61]. Patients can be referred to specific
substance abuse treatment programs as well as to self-
help programs such as Alcoholics Anonymous. Medical
management of alcoholism is effective and can include
the use of naltrexone or acamprosate [62]. These drugs
are relatively underused medications which can reduce
the incidence of relapse to alcoholic drinking [63]. Side
effects are relatively minor, and in some alcoholics,
these drugs can have a marked effect [64].
Psychological intervention as a treatment for aggression
In addition to any prescribed medical treatment, patients
must recognize their need to change, assume responsibility
for their behavior and begin to deal with conflict in a posi-
tive manner. To facilitate these cognitive processes, violent
individuals are commonly offered anger management or
behavioral therapies [65-68].
Psychological interventions can be very helpful for some
aggressive individuals [69], and effects can last for months,
even years after the therapy is terminated [66-68]. In a
meta-analysis looking at 50 studies, angry, (and in some
cases violent), patients treated with a variety of cognitive
behavioral therapy (CBT) treatments had better outcomes
than 76% of non-treated control patients [70]. These stu-
dies considered inpatients and outpatients, children and
adults, abusive parents and spouses, prisoners and indivi-
duals with mental retardation as well as the general popu-
lation. The most effective CBT anger management
programs include two or all three of the following compo-
nents: relaxation techniques, cognitive interventions and
communication skills [71]. For individuals with borderline
personality disorder, dialectical-behavioral therapy (DBT)
is an effective therapy [72,73]. The success of psychological
interventions on domestic violence recidivism is contro-
versial, but a meta-analysis of 22 studies suggests that the
effect size of therapy is generally significant though small
[65]. Treatments specifically for domestic violence include
feminist psycho-educational men’s groups, (that is, the
Duluth model) [68], men’s CBT groups, anger manage-
ment and couples’ therapy [65]. Many states regulate the
therapy of domestic abusers and, in some cases, restrict
the use of couple’s therapy or the consideration of neuro-
psychiatric issues (for example, alcoholism); the extent to
which such legislation inhibits potentially beneficial treat-
ment has not been evaluated [74]. Recently, a computer
assisted treatment adjunct based on a Trans Theoretical
Model of behavior change has been shown to reduce vio-
lence, suggesting that entirely new treatment paradigms
could be developed in the future [75]. The effectiveness of
domestic violence treatment is difficult to study, and the
problem is compounded by the effect of high dropout
rates (40% to 60% within three months), which predict
poor outcome [69]. A positive correlation has been found
repeatedly between the strength of the therapeutic alliance,
patient attendance rates and the overall likelihood of the
participant benefiting from the treatment [76,77]. There-
fore, when referring aggressive patients for therapy, a phy-
sician should supply several options and emphasize the
importance of finding a therapist with whom the patient
feels comfortable. In the United States, the American Psy-
chological Association (1-800-964-2000) or the National
Domestic Violence Hotline (1-800-799-SAFE) can provide
referral information.
Legal and ethical issues in the United States
While the American Medical Association’s Ethics Code
requires and emphasizes the importance of patient confi-
dentiality, it also states the following: “When a patient
Table 2 Examples of some agents used to reduce violence and aggression
Medications for
alcoholism
Naltrexone and acamprosate in sober alcoholics to reduce craving and relapse [63,64]; prazosin in alcoholism with PTSD
for caving and relapse [127].
Nutritional factors Essential omega 3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acids (EPA) in bipolar disorder and
borderline personality disorder; multiple vitamins and minerals with DHA and EPA in young male prisoners, and in children
[53,57-59,128].
Lithium In children and adults, in personality disorders, and in combination with other anticonvulsants or atypical antipsychotics
[40,48].
Beta-blockers Propranolol in brain-injury, autism, schizophrenia, organic mental disorders [37,129].
Anticonvulsants Carbamazepine/oxcarbazepine in impulsive violence and in elderly [32,36]; phenytoin in prisoners and in intermittent
explosive disorder [32,38,49,130]; Topriamate in borderline personality disorder and in depression [40]; valproate/divalproex
in a variety of psychiatric conditions [32,40].
Antidepressants Flouxetine in personality disorders [131], and in domestic abuse when combined with Cognitive Behavioral Therapy (CBT)
and alcohol treatment [132]; trazodone in dementia associated aggression [133].
Atypical
antipsychotics
Clozapine in schizophrenia [33,134]; quetiapine in schizophrenia and bipolar disorder [33,40]; Loxapine in schizophrenic and
psychosis [40], olanzapine in schizophrenia and borderline personality disorder [33,40]; aripiprazole in schizophrenia, autism
spectrum disorders and borderline personality disorder [33,40]; risperidone in a variety of psychiatric illness [40].
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threatens to inflict serious bodily harm to another person
or to him or herself and there is a reasonable probability
that the patient may carry out the threat, the physician
should take reasonable precautions for the protection of
the intended victim, which may include notification of
law enforcement authorities...” (E-5.05 Confidentiality).
Additionally, in the landmark Tarasoff cases (Tarasoff v.
Regents of the University of California 1974 and 1976)
[78] the ruling established in the state of California a
legal duty of health workers to warn and protect potential
victims from a patient’s foreseeable violence. Since then,
some states have codified the health worker’s duty to
protect specifying how to discharge that duty, some states
have declined to uphold the duty to protect in court and
some states have not addressed the issue in court or leg-
islation [79]. In states where the duty to protect does
apply it is only operative when the patient identifies a
specific victim or has a history of violence and there is
substantial and compelling reason to believe that the
patient will be violent again. The health worker fulfils the
duty in most states by informing the relevant authorities,
warning the victim or having the patient hospitalized,
although a few states have additional requirements. For
victims who are minors, all 50 states have passed some
form of a mandatory abuse and neglect reporting law.
Some states mandate that the suspicion of domestic vio-
lence or elder abuse must be reported to the legal autho-
rities [80]. All states require reporting of suspected child
abuse [81]. When treating an adult victim, mandatory
reporting laws also vary by state and are based on the
type and circumstances of the injury; laws in all states are
listed in a 2002 article by Houry and colleagues [82]. For
more information on legal responsibilities as a physician,
the American Medical Association recommends contact-
ing the state licensing board. Screening a patient for vio-
lent activity can be unethical if a physician fails to discuss
the limits of confidentiality and any legal requirement of
the state to break confidentiality and involve the legal
system [83].
While knowledge of laws in one’s state of practice is
essential, experts in medical law strongly recommend
that clinicians approach the dangerousness of a patient
as a clinical rather than legal issue [79,84,85]. The pri-
mary determinants in a malpractice suit are the thor-
oughness of the clinicians’ assessment of a patient’s
potential for violence and the care with which options
of action were considered, rather than the accuracy of
the clinicians’ predictions [79]. Thorough mental status
examinations and substance use histories should be
documented with direct quotes from the patient. Careful
notes should be taken explaining why a certain course
of action was taken, what other options were considered
but opted against and why. The more potentially
dangerous the client, the more care one should take in
the documentation of the case [85].
Summary
Although it is unknown what proportion of explosive
rage and violent behavior can be successfully treated,
the price of ignoring treatment includes the staggering
cost of injuries that might be prevented, and an even
greater cost in shattered communities, broken families
and personal suffering. Various neurobiological disor-
ders can affect the processing of perceived threats by
the brain, leading to dysfunctional, violent behaviors.
Future research will add to our understanding of vio-
lence, but existing evidence clearly shows that physicians
today have a unique opportunity to address medical
aspects of this problem when they identify the perpetra-
tors of explosive violent behavior. Asking patients if
they lose their temper can identify violent individuals in
a non-judgmental way and can open the door to appro-
priate medical evaluation, treatment and referral.
Patients are given an important degree of self-determi-
nation when they are offered expanded treatment
options that include not only behavioral therapy, but
also nutritional supplementation, alcoholism treatment
and pharmaceuticals.
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